CN111315897B - 用于黑素瘤检测的方法 - Google Patents

用于黑素瘤检测的方法 Download PDF

Info

Publication number
CN111315897B
CN111315897B CN201880049298.1A CN201880049298A CN111315897B CN 111315897 B CN111315897 B CN 111315897B CN 201880049298 A CN201880049298 A CN 201880049298A CN 111315897 B CN111315897 B CN 111315897B
Authority
CN
China
Prior art keywords
expression level
cflar
hla
melanoma
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880049298.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN111315897A (zh
Inventor
I.莫林
M.基德
I.德罗斯多夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liquid Biopsy Research LLC
Original Assignee
Liquid Biopsy Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Research LLC filed Critical Liquid Biopsy Research LLC
Publication of CN111315897A publication Critical patent/CN111315897A/zh
Application granted granted Critical
Publication of CN111315897B publication Critical patent/CN111315897B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
CN201880049298.1A 2017-05-25 2018-05-21 用于黑素瘤检测的方法 Active CN111315897B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762511058P 2017-05-25 2017-05-25
US62/511058 2017-05-25
PCT/US2018/033658 WO2018217627A1 (en) 2017-05-25 2018-05-21 Methods for melanoma detection

Publications (2)

Publication Number Publication Date
CN111315897A CN111315897A (zh) 2020-06-19
CN111315897B true CN111315897B (zh) 2024-10-22

Family

ID=62620988

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880049298.1A Active CN111315897B (zh) 2017-05-25 2018-05-21 用于黑素瘤检测的方法

Country Status (14)

Country Link
US (2) US20180340934A1 (enExample)
EP (1) EP3631017B1 (enExample)
JP (1) JP7227964B2 (enExample)
KR (1) KR102763004B1 (enExample)
CN (1) CN111315897B (enExample)
AU (1) AU2018273844B2 (enExample)
BR (1) BR112019024481A2 (enExample)
CA (1) CA3064732A1 (enExample)
DK (1) DK3631017T3 (enExample)
ES (1) ES2920288T3 (enExample)
IL (1) IL270787B2 (enExample)
MX (1) MX2019014026A (enExample)
PL (1) PL3631017T3 (enExample)
WO (1) WO2018217627A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019024481A2 (pt) 2017-05-25 2020-07-14 Liquid Biopsy Research LLC métodos para detecção de melanoma
US20210108259A1 (en) 2019-10-10 2021-04-15 Liquid Biopsy Research LLC Compositions, methods and kits for biological sample and rna stabilization

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006203830A1 (en) * 2005-01-07 2006-07-13 The Johins Hopkins University Biomarkers for melanoma
CN101601042A (zh) * 2006-11-03 2009-12-09 贝勒研究院 通过血液白细胞微阵列分析诊断转移性黑色素瘤和监测免疫抑制的指示物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7615349B2 (en) * 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
EP2092075A2 (en) * 2006-11-06 2009-08-26 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
US20110070582A1 (en) * 2008-11-03 2011-03-24 Source Precision Medicine, Inc. d/b/d Source MDX Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects
US20110091384A1 (en) * 2009-10-13 2011-04-21 The Johns Hopkins University Biomarker for identification of melanoma tumor cells
US20140045915A1 (en) * 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
CN104470920A (zh) * 2012-07-03 2015-03-25 通益制药有限公司 固态形式的维罗菲尼胆碱盐
AU2015317893B2 (en) * 2014-09-15 2021-05-20 Clifton Life Sciences LLC Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
BR112019024481A2 (pt) 2017-05-25 2020-07-14 Liquid Biopsy Research LLC métodos para detecção de melanoma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006203830A1 (en) * 2005-01-07 2006-07-13 The Johins Hopkins University Biomarkers for melanoma
CN101601042A (zh) * 2006-11-03 2009-12-09 贝勒研究院 通过血液白细胞微阵列分析诊断转移性黑色素瘤和监测免疫抑制的指示物

Also Published As

Publication number Publication date
DK3631017T3 (da) 2022-06-20
JP7227964B2 (ja) 2023-02-22
EP3631017A1 (en) 2020-04-08
MX2019014026A (es) 2020-08-03
PL3631017T3 (pl) 2022-09-26
WO2018217627A1 (en) 2018-11-29
IL270787B2 (en) 2023-08-01
AU2018273844A1 (en) 2019-12-19
JP2020524524A (ja) 2020-08-20
US20180340934A1 (en) 2018-11-29
BR112019024481A2 (pt) 2020-07-14
ES2920288T3 (es) 2022-08-02
IL270787B1 (en) 2023-04-01
KR102763004B1 (ko) 2025-02-04
EP3631017B1 (en) 2022-03-23
KR20200030034A (ko) 2020-03-19
US12399179B2 (en) 2025-08-26
IL270787A (en) 2020-01-30
CN111315897A (zh) 2020-06-19
AU2018273844B2 (en) 2024-11-14
US20230022236A1 (en) 2023-01-26
CA3064732A1 (en) 2018-11-29

Similar Documents

Publication Publication Date Title
JP5940517B2 (ja) 内分泌治療下における乳癌再発を予測するための方法
JP6408380B2 (ja) 癌を患うリスクのある被検体を診断するための方法およびキット
US20200131586A1 (en) Methods and compositions for diagnosing or detecting lung cancers
RU2737449C1 (ru) Система для предсказания прогноза и пользы от вспомогательной химиотерапии для больных раком желудка ii и iii стадии
JP2008536488A (ja) 遺伝子発現署名を使用する、癌による死亡および前立腺癌生存率を予測するための方法および組成物
WO2008070301A9 (en) Predicting lung cancer survival using gene expression
JP2020535827A (ja) マイクロｒｎａ遺伝子発現を使用して黒色腫を診断し、病期分類し、モニタリングする方法
US20250137066A1 (en) Compostions and methods for diagnosing lung cancers using gene expression profiles
JP2024523848A (ja) 癌検出方法、キットおよびシステム
KR20210044233A (ko) 흑색종의 전이 및 환자의 예후를 예측하기 위한 유전자 서명
CN111194356A (zh) 用于检测浆细胞恶病质的方法
CN111315897B (zh) 用于黑素瘤检测的方法
CN110573629B (zh) 用于诊断早期胰腺癌的方法和试剂盒
JP6784673B2 (ja) 膵臓がんに冒された患者の生存予後を判断する方法
JP7313374B2 (ja) Ｔｍｐｒｓｓ２－ｅｒｇ融合状態により選択された、ｐｄｅ４ｄ変異発現、及び術後の臨床変数に基づく、術後リスクの層別化
AU2024237081A1 (en) Methods of developing cancer diagnostic models and uses thereof in developing cancer detection methods
CN120380169A (zh) 用于在唾液中检测神经内分泌癌的方法
CN117120631A (zh) 滤泡性甲状腺癌特异性标志物
CN120380170A (zh) 用于唾液中的前列腺癌检测的方法
HK40017741A (en) Methods for melanoma detection
HK40017741B (en) Methods for melanoma detection
KR20200038045A (ko) 방광암 수술치료법 결정을 위한 유전자 세트

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant